- Home
- PRT vs VERU Comparison
PRT vs VERU Comparison
Compare PRT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- VERU
- Stock Information
- Founded
- PRT 2017
- VERU 1971
- Country
- PRT United States
- VERU United States
- Employees
- PRT N/A
- VERU N/A
- Industry
- PRT Oil & Gas Production
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- PRT Energy
- VERU Health Care
- Exchange
- PRT Nasdaq
- VERU Nasdaq
- Market Cap
- PRT 47.7M
- VERU 54.6M
- IPO Year
- PRT N/A
- VERU 1990
- Fundamental
- Price
- PRT $3.95
- VERU $4.29
- Analyst Decision
- PRT
- VERU Strong Buy
- Analyst Count
- PRT 0
- VERU 3
- Target Price
- PRT N/A
- VERU $33.33
- AVG Volume (30 Days)
- PRT 35.1K
- VERU 158.4K
- Earning Date
- PRT 11-12-2025
- VERU 08-12-2025
- Dividend Yield
- PRT 10.75%
- VERU N/A
- EPS Growth
- PRT 1.16
- VERU N/A
- EPS
- PRT 0.44
- VERU N/A
- Revenue
- PRT $6,314,770.00
- VERU $16,886,419.00
- Revenue This Year
- PRT N/A
- VERU N/A
- Revenue Next Year
- PRT N/A
- VERU N/A
- P/E Ratio
- PRT $8.93
- VERU N/A
- Revenue Growth
- PRT 1.82
- VERU 337.24
- 52 Week Low
- PRT $3.26
- VERU $2.64
- 52 Week High
- PRT $4.63
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- PRT 52.30
- VERU 74.55
- Support Level
- PRT $3.84
- VERU $3.75
- Resistance Level
- PRT $3.99
- VERU $3.99
- Average True Range (ATR)
- PRT 0.08
- VERU 0.24
- MACD
- PRT 0.01
- VERU -0.01
- Stochastic Oscillator
- PRT 71.23
- VERU 94.34
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.